Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) Short Interest Update

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) was the target of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 2,300 shares, a decline of 98.7% from the October 15th total of 174,700 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 161,000 shares, the days-to-cover ratio is presently 0.0 days.

Lipella Pharmaceuticals Price Performance

NASDAQ LIPO opened at $2.64 on Thursday. Lipella Pharmaceuticals has a 12 month low of $2.24 and a 12 month high of $12.00. The company has a market capitalization of $3.19 million, a price-to-earnings ratio of -0.55 and a beta of 0.31. The firm’s fifty day moving average price is $3.32 and its 200 day moving average price is $4.17.

Lipella Pharmaceuticals (NASDAQ:LIPO) last posted its earnings results on Tuesday, August 13th. The company reported ($0.96) earnings per share for the quarter. The firm had revenue of $0.14 million during the quarter. Lipella Pharmaceuticals had a negative net margin of 817.16% and a negative return on equity of 172.07%.

Lipella Pharmaceuticals Company Profile

Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).